Cancer research

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

Retrieved on: 
Tuesday, September 12, 2023

BELTSVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of Phase 2 clinical data by collaborators at the Yale Cancer Center demonstrating clinical benefit in patients with advanced, PD-1 axis inhibitor refractory non-small cell lung cancer (NSCLC) treated with a combination regimen of NC318, a Siglec-15 (S15) monoclonal antibody (mAb), and pembrolizumab, an anti-PD-1 antibody.

Key Points: 
  • In an earlier monotherapy study from NextCure, NC318 demonstrated single agent activity in a Phase 1/2 dose escalation trial (NCT03665285) for patients with advanced solid tumors (Tolcher et al, SITC 2019).
  • The ongoing NCT04699123 study is a randomized trial designed to assess the safety and efficacy of NC318 alone or in combination with pembrolizumab.
  • The combination portion of the study is assessing efficacy in NSCLC subjects who have experienced disease progression on, or after, PD-1 axis inhibitor therapy.
  • NC318 infusion reactions were seen in seven patients (three Grade 3, four Grade 2), six receiving the combination and one NC318 alone.

Element Biosciences Establishes Scientific Advisory Board

Retrieved on: 
Monday, August 14, 2023

SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.

Key Points: 
  • SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.
  • Element's Scientific Advisory Board will provide guidance and direction for research, development, and product innovation as the company continues its success and expansion in the genomics industry.
  • "With this diverse and accomplished group of scientists from across the globe, our Scientific Advisory Board empowers us to reach new heights in research and product innovation," said Michael Previte, PhD, Element CTO, SVP of R&D, and co-founder.
  • "I am thrilled to lead Element's Scientific Advisory Board," said Joseph (Jody) Puglisi, Jauch Professor in the Department of Structural Biology at Stanford University School of Medicine and Element's Scientific Advisory Board chair.

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Retrieved on: 
Thursday, August 10, 2023

HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).

Key Points: 
  • HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).
  • In cancer, PGE2 acts in the tumor microenvironment to trigger cancer cells to evade the immune system.
  • Phase IIa of the trial will expand the optimal combination dose in up to four cohorts in specified cancer indications.
  • Sosei Heptares holds a license to the results generated under the trial to continue the clinical development and commercialization of HTL0039732.

Flow Cytometry Market worth $7.0 billion | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023

In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.

Key Points: 
  • In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
  • In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
  • These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.

Flow Cytometry Market worth $7.0 billion | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023

In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.

Key Points: 
  • In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
  • In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
  • Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
  • These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.

Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001

Retrieved on: 
Tuesday, August 8, 2023

Aleta Biotherapeutics (Aleta), a privately-held immuno-oncology company with a platform of CAR T-Cell Engagers (CTE) which enable cell therapies to improve outcomes for patients with cancer, announces that the U.K.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a privately-held immuno-oncology company with a platform of CAR T-Cell Engagers (CTE) which enable cell therapies to improve outcomes for patients with cancer, announces that the U.K.
  • Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorization (CTA) to evaluate investigational biologic ALETA-001 in a Phase 1/2 clinical trial in the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T-cell therapy.
  • Aleta’s lead program, ALETA-001 has clinical support and funding from its collaboration partner, Cancer Research UK’s Centre for Drug Development, which has sponsored and will conduct the Phase 1/2 clinical trial.
  • “The authorization to clinically evaluate, in collaboration with Cancer Research UK, the potent activity of ALETA-001, our lead biologic CAR T-Cell Therapy Engager, marks important progress for the entire global oncology community - especially patients,” commented Paul Rennert, Ph.D., Chief Executive Officer and Chief Scientific Officer, Aleta Biotherapeutics.

Adrestia Acquired by Insmed Incorporated, Bringing its Novel Approach to Tackling Intractable Genetic Diseases to Insmed’s Early-Stage Research Portfolio

Retrieved on: 
Thursday, August 3, 2023

“Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.

Key Points: 
  • “Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.
  • With Insmed, we’re no longer dreaming big, we’re going big.”
    Adrestia’s synthetic rescue platform uses whole genome assays to identify drug targets for genetic diseases in a wide network of functionally connected genes.
  • Sir Steve is University of Cambridge Professor of Biology and Senior Group Leader at the Cancer Research UK Cambridge Institute.
  • J.P. Morgan Securities plc acted as exclusive financial adviser to Adrestia, and Goodwin Procter (UK) LLP acted as Adrestia’s legal counsel.

NK:IO Raises £1.2M, Bringing Total Seed Funding to £5.1M, to Advance Pioneering NK Cell Therapy

Retrieved on: 
Tuesday, July 25, 2023

This brings total equity financing to £3.2M and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into development.

Key Points: 
  • This brings total equity financing to £3.2M and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into development.
  • NK:IO is based on pioneering discoveries in NK cell biology from Hugh J M Brady, Professor of Immunology and Matt Fuchter, Professor of Chemistry, at Imperial College.
  • NK:IO is exploiting these in its unique platform which activates blood stem cell progenitors to yield industry-leading NK cell tumour-killing potency and very high yield cell production, which it believes will be transformative in cancer cell therapy.
  • This includes development of a manufacturing process in collaboration with the Cell and Gene Therapy Catapult, whose mission is to support the UK’s cell and gene therapy industry.

Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

Retrieved on: 
Monday, July 24, 2023

All eight subjects enrolled and treated completed the full per protocol vaccination regimen, which consisted of six-consecutive weekly intradermal (ID) injections of 1 x 107 viable VAC2 cells.

Key Points: 
  • All eight subjects enrolled and treated completed the full per protocol vaccination regimen, which consisted of six-consecutive weekly intradermal (ID) injections of 1 x 107 viable VAC2 cells.
  • Overall, VAC2 was well-tolerated, there were no unexpected SAEs, and there were no dose limiting toxicities.
  • Brian Culley, Chief Executive Officer of Lineage, added: “The conclusion of this partnered study represents an important milestone for Lineage’s allogeneic cell therapy pipeline.
  • Lineage, Cancer Research UK, and the participating investigators intend to present these data at future medical and scientific conferences and submit publications to relevant journals for peer review.

Kytopen Announces Collaboration with leading bioengineer Omid Veiseh, PhD. to Fuel Genome Engineering Research and Accelerate Cell Therapy Discovery

Retrieved on: 
Tuesday, July 11, 2023

This collaboration aims to drive cutting-edge research in genome engineering and expedite the discovery of novel cell therapies.

Key Points: 
  • This collaboration aims to drive cutting-edge research in genome engineering and expedite the discovery of novel cell therapies.
  • "Cell therapy discovery holds tremendous promise for addressing challenging diseases such as cancer and rare disorders.
  • Translational Medical Research Centers, such as Rice University, play a vital role in spearheading innovative medical therapeutic research."
  • "This collaboration exemplifies our dedication to solving cell therapy manufacturing problems at the discovery stage."